UK signs off on Sanofi, As­traZeneca's RSV an­ti­body four days af­ter Eu­rope

3 years ago
Pharma

As­traZeneca dou­bles down on COPD aware­ness ef­forts dur­ing na­tion­al aware­ness month

3 years ago
Pharma
Marketing

On­col­o­gists re­spond best to short, pre­cise and da­ta-rich mar­ket­ing mes­sages, study finds

3 years ago
Pharma
Marketing

No­var­tis cuts 275 jobs at Illi­nois site to con­sol­i­date Zol­gens­ma man­u­fac­tur­ing in North Car­oli­na

3 years ago
People
Pharma

Ipsen claims pos­i­tive PhI­II in drug once owned by Mer­ri­mack, whose shares jump pend­ing pos­si­ble nine-fig­ure pay­out

3 years ago
R&D

No­vavax tem­pers its rev­enue ex­pec­ta­tions as it un­veils PhI­II da­ta for bi­va­lent boost­er

3 years ago
R&D
Pharma

As an Am­gen's PhI­II car­dio plan takes shape, Roy­al­ty Phar­ma snags a stake in fu­ture sales

3 years ago
Deals

Up­dat­ed: Two years af­ter launch, Third Rock-backed neu­ro start­up Faze Med­i­cines is clos­ing its doors — re­port

3 years ago
Startups
R&D

Up­dat­ed: Af­ter a tor­tured run with a weak PARP play­er and cash fast run­ning out, Clo­vis sig­nals like­ly bank­rupt­cy, ...

3 years ago
People
Deals

Catch­ing up with Keytru­da, Re­gen­eron scores front­line NSCLC ap­proval for Lib­tayo/chemo com­bo

3 years ago
Pharma
FDA+

GSK vets the­o­rize that a mi­to­chon­dr­i­al tar­get may un­lock Parkin­son's and ALS treat­ments in new start­up

3 years ago
Financing
Startups

FDA ad­comm of­fers thumbs up on As­traZeneca's 2-in-1 asth­ma in­haler — but on­ly for adults

3 years ago
R&D
FDA+

Not a home run, but first base: GSK un­wraps PhII da­ta on he­pati­tis B treat­ment in pur­suit of ‘func­tion­al cure’

3 years ago
R&D

Nor­bert Bischof­berg­er ices a PhI­II AML drug — for the sec­ond time in his ca­reer

3 years ago
R&D

Bay­er CEO talks next steps on in­fla­tion, sup­ply chain sta­bil­i­ty amid Q3 growth

3 years ago
Pharma

Am­gen may be way late to the obe­si­ty game, but the mar­ket scouts are lov­ing the block­buster po­ten­tial of AMG 133

3 years ago
Bioregnum
R&D

Twit­ter ad­ver­tis­ing pause or per­sist? Phar­mas qui­et­ly weigh op­tions in un­cer­tain time

3 years ago
Pharma
Marketing

By the num­bers: As the pan­dem­ic biotech boom fades, it's be­gin­ning to look a lot like 2019 — or be­fore

3 years ago
Deals

Start­ing with ADC, FDA calls for ful­ly en­rolled con­fir­ma­to­ry tri­al pri­or to ac­cel­er­at­ed ap­proval sub­mis­sion

3 years ago
R&D

While PhI­II Parkin­son's tri­als go slow­er than ex­pect­ed, Cerev­el pre­views plans to raise $900M

3 years ago
Financing
R&D

Adap­ti­m­mune trims pipeline, un­veils plans to lay off 25%+ of em­ploy­ees amid sweet­ened ES­MO da­ta

3 years ago
People

J&J, Idor­sia build out piv­otal dataset for their $230M hy­per­ten­sion drug, show­ing a main­tained re­sponse

3 years ago
R&D

MRx roundup: J&J’s Janssen ‘Save Legs’ cam­paign de­tails first-year re­sults; AZ and Lil­ly both roll new tech ...

3 years ago
Pharma
Marketing

In lat­est AI tie-up, Sanofi part­ners with In­sil­i­co for six new tar­gets

3 years ago
Deals
R&D
First page Previous page 431432433434435436437 Next page Last page
A service from the Financial Times